Drug Profile
Atorvastatin/glimepiride
Alternative Names: Glimepiride/atorvastatinLatest Information Update: 10 Jul 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Antihyperglycaemics; Antihyperlipidaemics; Fatty acids; Heptanoic acids; Pyrroles; Sulfones; Sulfonylureas
- Mechanism of Action HMG-CoA reductase inhibitors; Potassium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 23 Jan 2018 Discontinued - Phase-III for Type-2 diabetes mellitus in Mexico, Philippines, Russia, Thailand, Malaysia, South Korea (PO)